|
Published by: Medtech Insight
Published: Jan. 1, 2007 - 207 Pages
Table of Contents
- EXECUTIVE SUMMARY
- i. Methodology
- ii. Major Wound Types
- iii. Skin Replacements/Substitutes
- iv. Active Wound Repair Modulators
- v. Combined Market Forecast
- Exhibit ES-1: Major Wound Types, by Cause
- Exhibit ES-2: Europe, Skin Replacements/Substitutes, Market Forecast, by Country, 2002-2012
- Exhibit ES-3: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2002-2012
- Exhibit ES-4: Skin Replacements/Substitutes and Active Wound Repair Modulators, Combined Market Forecast, 2002-2012
- 1. EUROPEAN HEALTHCARE MARKETS
- 1.1 The European Union
- 1.1.1 A Common Currency
- 1.1.2 Regulatory Policies
- 1.1.3 Reimbursement
- 1.1.4 Healthcare Spending
- 1.2 Selected European National Healthcare Profiles
- 1.2.1 France
- 1.2.1.1 Healthcare Organization and Reform
- 1.2.1.2 Hospital Services
- 1.2.1.3 Medical Device Reimbursement
- 1.2.2 Germany
- 1.2.2.1 Healthcare Organization and Reform
- 1.2.2.2 Hospital Services
- 1.2.2.3 Medical Device Reimbursement
- 1.2.3 Italy
- 1.2.3.1 Healthcare Organization and Reform
- 1.2.3.2 Hospital Services
- 1.2.3.3 Medical Device Reimbursement
- 1.2.4 Spain
- 1.2.4.1 Healthcare Organization and Reform
- 1.2.4.2 Hospital Services
- 1.2.4.3 Medical Device Reimbursement
- 1.2.5 United Kingdom
- 1.2.5.1 Healthcare Organization and Reform
- 1.2.5.2 Hospital Services
- 1.2.5.3 Medical Device Reimbursement
- 1.2.6 Benelux
- 1.2.6.1 Healthcare Organization and Reform
- 1.2.6.1.1 Belgium
- 1.2.6.1.2 Luxembourg
- 1.2.6.1.3 The Netherlands
- 1.2.6.2 Hospital Services
- 1.2.6.3 Medical Device Reimbursement
- 1.2.7 Nordic Countries
- 1.2.7.1 Healthcare Organization and Reform
- 1.2.7.1.1 Denmark
- 1.2.7.1.2 Finland
- 1.2.7.1.3 Norway
- 1.2.7.1.4 Sweden
- 1.2.7.2 Hospital Services
- 1.2.7.3 Medical Device Reimbursement
- Exhibit 1-1: European Union, Medical Devices Risk Classification System
- Exhibit 1-2: European Union, Population Statistics Comparison, 1995 and 2005
- Exhibit 1-3: France, Selected National Healthcare Statistics
- Exhibit 1-4: Germany, Selected National Healthcare Statistics
- Exhibit 1-5: Italy, Selected National Healthcare Statistics
- Exhibit 1-6: Spain, Selected National Healthcare Statistics
- Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics
- Exhibit 1-8: Belgium, Selected National Healthcare Statistics
- Exhibit 1-9: Luxembourg, Selected National Healthcare Statistics
- Exhibit 1-10: The Netherlands, Selected National Healthcare Statistics
- Exhibit 1-11: Denmark, Selected National Healthcare Statistics
- Exhibit 1-12: Finland, Selected National Healthcare Statistics
- Exhibit 1-13: Norway, Selected National Healthcare Statistics
- Exhibit 1-14: Sweden, Selected National Healthcare Statistics
- 2. CLINICAL ISSUES IN WOUND MANAGEMENT
- 2.1 Physiology of Wound Closure
- 2.1.1 Layers of the Skin and Supporting Structures
- 2.1.1.1 Epidermis
- 2.1.1.2 Dermis
- 2.1.1.3 Subcutaneous Tissue
- 2.1.1.4 Fascia
- 2.1.1.5 Muscle
- 2.1.1.6 Bone
- 2.1.2 Wound Closure Process
- 2.1.2.1 Hemostasis
- 2.1.2.2 Inflammation
- 2.1.2.3 Proliferation
- 2.1.2.4 Remodeling Phase
- 2.2 Factors Affecting Wound Closure
- 2.2.1 Extrinsic Factors
- 2.2.1.1 Desiccation
- 2.2.1.2 Hydration
- 2.2.1.3 Infection
- 2.2.1.4 Maceration
- 2.2.1.5 Medications and Other Types of Treatment
- 2.2.1.6 Necrotic Tissue and Debris
- 2.2.1.7 Oxygenation
- 2.2.1.8 Stress
- 2.2.1.9 Temperature
- 2.2.1.10 Wound Creation and Depth
- 2.2.1.11 Wound Closure Techniques
- 2.2.1.12 Other Extrinsic Factors
- 2.2.2 Intrinsic Factors
- 2.2.2.1 Body Build
- 2.2.2.2 Chronic Illness and Age
- 2.2.2.3 Nutrition
- 2.2.3 Complications of Wound Healing
- 2.2.3.1 Bleeding
- 2.2.3.2 Scarring
- 2.3 Major Wound Types
- 2.3.1 Amputation
- 2.3.2 Arterial Ulcers
- 2.3.3 Burns
- 2.3.4 Diabetic Ulcers
- 2.3.5 Pressure Ulcers
- 2.3.6 Surgical Wounds
- 2.3.7 Traumatic Wounds
- 2.3.8 Venous Ulcers
- Exhibit 2-1: Layers of the Skin and Supporting Structures
- Exhibit 2-2: Phases of the Wound Closure Process
- Exhibit 2-3: Intrinsic and Extrinsic Factors Affecting Wound Closure
- Exhibit 2-4: Major Wound Types, by Cause
- Exhibit 2-5: Stages of Burn Wounds
- Exhibit 2-6: Stages of Pressure Ulcers
- Exhibit 2-7: 2005, Surgical Procedure Volumes
- 3. SKIN REPLACEMENTS/SUBSTITUTES
- 3.1 Allografts
- 3.2 Autografts
- 3.3 Xenografts
- 3.4 Amniotic Membranes
- 3.5 Autologous and Tissue-Engineered Skin Replacements/Substitutes
- 3.5.1 Epidermal Equivalents
- 3.5.2 Dermal Equivalents
- 3.5.3 Composite Bilayer Skin Equivalents
- 3.6 Market Analysis
- 3.7 Competitive Analysis
- Exhibit 3-1: Advantages and Disadvantages of Allografts
- Exhibit 3-2: 2007, Selected Epidermal Equivalent Skin Substitutes
- Exhibit 3-3: 2007, Selected Dermal Equivalent Skin Substitutes
- Exhibit 3-4: 2007, Selected Composite Bilayer Equivalent Skin Substitutes
- Exhibit 3-5: Europe, Skin Replacements/Substitutes, Market Forecast, by Country, 2002-2012
- Exhibit 3-6: 2005, Europe, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-7: 2005, France, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-8: 2005, Germany, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-9: 2005, Italy, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-10: 2005, Spain, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-11: 2005, United Kingdom, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-12: 2005, Benelux Countries, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-13: 2005, Nordic Countries, Skin Replacements/Substitutes Market, Share by Supplier
- Exhibit 3-14: 2005, Rest of Europe, Skin Replacements/Substitutes Market, Share by Supplier
- 4. ACTIVE WOUND REPAIR MODULATORS
- 4.1 Topical Antimicrobials
- 4.1.1 Products
- 4.1.2 Market Analysis
- 4.1.3 Competitive Analysis
- 4.2 Growth Factors
- 4.2.1 Classification of Growth Factors
- 4.2.1.1 Fibroblast Growth Factor
- 4.2.1.2 Transforming Growth Factors
- 4.2.1.3 Epidermal Growth Factors
- 4.2.1.4 Platelet-Derived Growth Factors
- 4.2.1.5 Insulin-Like Growth Factors
- 4.2.1.6 Keratinocyte Growth Factors
- 4.2.1.7 Vascular Endothelial Growth Factors
- 4.2.1.8 Autologous Growth Factors
- 4.2.1.8.1 Biomet Biologics/Biomet
- 4.2.1.8.2 Cytomedix
- 4.2.1.8.3 Harvest Technologies
- 4.2.1.8.4 Medtronic
- 4.2.1.8.5 PlasmaSeal/Hanuman Medical
- 4.2.1.9 Angiogenic Growth Factors
- 4.2.2 Competitors and Products
- 4.2.3 Market Analysis
- 4.3 Gene Therapy Agents
- 4.4 Other Active Wound Repair Modulators
- 4.4.1 Antibiotics and Anti-Infectives
- 4.4.2 Hormones
- 4.4.3 Matrix Metalloproteinase Enzyme Inhibitors
- 4.4.4 Neuropeptides in Diabetic Wounds
- 4.4.5 Stem Cells
- 4.4.6 Other Products
- Exhibit 4-1: 2007, Selected Topical Antimicrobial Products
- Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2002-2012
- Exhibit 4-3: 2005, Europe, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-4: 2005, France, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-5: 2005, Germany, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-6: 2005, Italy, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-7: 2005, Spain, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-8: 2005, United Kingdom, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-9: 2005, Benelux Countries, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-10: 2005, Nordic Countries, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-11: 2005, Rest of Europe, Topical Antimicrobial Products Market, Share by Supplier
- Exhibit 4-12: 2007, Selected Growth Factors Developed for Wound Healing Applications
- Exhibit 4-13: 2006, Selected Angiogenic Growth Factors
- Exhibit 4-14: Europe, Growth Factors, Market Forecast, 2002-2012
- Exhibit 4-15: Preclinical Gene Therapy Studies, 1998-2004
- 5. COMPANY PROFILES
- 5.1 DFB Pharmaceuticals, Inc.
- 5.2 GlaxoSmithKline PLC
- 5.3 Integra LifeSciences Holdings Corporation
- 5.4 Johnson & Johnson Wound Management/Ethicon, Inc./ Johnson & Johnson
- 5.5 LEO Laboratories LTD
- 5.6 Mylan Pharmaceuticals, Inc./Mylan Laboratories, Inc
- 5.7 Ortec International, Inc
- 5.8 Pfizer, Inc
- 5.9 Sanofi-aventis
- 5.10 Smith & Nephew PLC
- APPENDIX: COMPANY LISTING
AbstractIn 2005, the European skin replacements/ substitutes and active wound repair modulators market totaled approximately $252 million, with skin replacements/substitutes accounting for 21% of sales and active wound repair modulators accounting for the remaining 79% of sales. Over the forecast period covered by this report, total sales are expected to increase at a compound annual rate of 6.6%, reaching approximately $395 million in the year 2012.
This report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements/substitutes and active wound repair modulators market. Topics discussed in this report include an overview of the healthcare markets of France, Germany, Italy, Spain, the United Kingdom, the Benelux countries, and the Nordic countries; an overview of clinical issues in wound management; skin replacements/ substitutes such as allografts, autografts, xenografts, and tissue-engineered skin equivalents; and active wound repair modulators such as topical antimicrobials, growth factors, and gene therapy agents.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
